U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,481.05
    +309.53 (+1.28%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Celldex Therapeutics Raises $250M Via Equity To Support Development Of Skin Disease Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public offering of around 5.9 million shares at .00 per share, representing a discount of about 6% from the last close price of $44.6 on Tuesday.

  • Gross proceeds are expected to approximately $250 million.

  • The Company previously announced to offer 5 million in shares.

  • Underwriters have an option to purchase up to an additional 892,857 shares.

  • Jefferies, SVB Leerink, Guggenheim Securities, and Cantor are acting as the joint book-running managers for the offering.

  • LifeSci Capital LLC and H.C. Wainwright & Co. are acting as co-lead managers for the offering.

  • Celldex will use the proceeds to fund the development of CDX-0159 and for general corporate purposes.

  • The offering will close by July 16.

  • Recently, the Company shared positive Phase 1b trial data of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism.

  • Price Action: CLDX shares are down 2.65% at $43.42 premarket on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.